In a preclinical model of B cell leukemia, introducing a CD19 CAR into the T cell receptor alpha chain constant (TRAC) locus with CRISPR-Cas9 reduced both median CAR expression and expression variability compared with a virally engineered control.23 TRAC knock-in also significantly improved tumor clearance compared with virally modified controls. Here, TRAC is linked to neoplasm.